Ursodeoxycholic Acid Ameliorates Pain Severity and Cartilage Degeneration in Monosodium Iodoacetate-Induced Osteoarthritis in Rats

다국어 초록 (Multilingual Abstract)

Osteoarthritis (OA) is a degenerative joint disease characterized by a progressive loss of cartilage. And, increased oxidative stress plays a relevant role in the pathogenesis of OA. Ursodeoxycholic acid (UDCA) is a used drug for liver diseases known for its free radical-scavenging property. The objectives of this study were to investigate the in vivo effects of UDCA on pain severity and cartilage degeneration using an experimental OA model and to explore its mode of actions. OA was induced in rats by intra-articular injection of monosodium iodoacetate (MIA) to the knee. Oral administration UDCA was initiated on the day of MIA injection. Limb nociception was assessed by measuring the paw withdrawal latency and threshold. Samples were analyzed macroscopically and histologically. Immunohistochemistry was used to investigate the expression of interleukin-1β (IL-1β), IL-6, nitrotyrosine and inducible nitric oxide synthase (iNOS) in knee joints. UDCA showed an antinociceptive property and attenuated cartilage degeneration. OA rats given oral UDCA significantly exhibited a decreased number of osteoclasts in subchondral bone legion compared with the vehicle-treated OA group. UDCA reduced the expression of IL-1β, IL-6, nitrotyrosine and iNOS in articular cartilage. UDCA treatment significantly attenuated the mRNA expression of matrix metalloproteinase-3 (MMP-3), -13, and ADAMTS5 in IL-1β-stimulated human OA chondrocytes. These results show the inhibitory effects of UDCA on pain production and cartilage degeneration in experimentally induced OA. The chondroprotective properties of UDCA were achieved by suppressing oxidative damage and inhibiting catabolic factors that are implicated in the pathogenesis of cartilage damage in OA.

참고문헌 (Reference)

1 Okada, K., "Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am" 295 : G735-G747, 2008

2 Poupon, R., "Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action" 36 (36): S3-S12, 2012

3 Corpechot, C., "The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis" 128 : 297-303, 2005

4 Kuettner, K. E., "Synthesis of cartilage matrix by mammalian chondrocytes in vitro. I. Isolation, culture characteristics, and morphology" 93 : 743-750, 1982

5 Scott, J. L., "Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease" 69 : 1502-1510, 2010

6 Chadjichristos, C., "Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes" 278 : 39762-39772, 2003

7 Kobayashi, K., "Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats" 65 : 1195-1199, 2003

8 Pelletier, J. P., "Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level" 43 : 1290-1299, 2000

9 Chevalier, X., "Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study" 32 : 1317-1323, 2005

10 Kapoor, M., "Role of proinflammatory cytokines in the pathophysiology of osteoarthritis" 7 : 33-42, 2011

11 Cotofana, S., "Relationship between knee pain and the presence, location, size and phenotype of femorotibial denuded areas of subchondral bone as visualized by MRI" 21 : 1214-1222, 2013

12 Najim, R. A., "Oxidative stress in patients with Behcet's disease: I correlation with severity and clinical parameters" 34 : 308-314, 2007

13 Guzman, R. E., "Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis" 31 : 619-624, 2003

14 Tiku, M. L., "Malondialdehyde oxidation of cartilage collagen by chondrocytes" 11 : 159-166, 2003

15 Durigova, M., "MMPs are less efficient than ADAMTS5 in cleaving aggrecan core protein" 30 : 145-153, 2011

16 Dean, D. D., "Levels of metalloproteases and tissue inhibitor of metalloproteases in human osteoarthritic cartilage" 14 (14): 43-44, 1987

17 Sanghi, D., "Is radiology a determinant of pain, stiffness, and functional disability in knee osteoarthritis? A cross-sectional study" 16 : 719-725, 2011

18 Sharma, A. R., "Interplay between Cartilage and Subchondral Bone Contributing to Pathogenesis of Osteoarthritis" 14 : 19805-19830, 2013

19 Carlo, M. D. Jr., "Increased oxidative stress with aging reduces chondrocyte survival: correlation with intracellular glutathione levels" 48 : 3419-3430, 2003

20 Guerne, P. A., "IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro" 144 : 499-505, 1990

21 Mendes, A. F., "Hydrogen peroxide mediates interleukin-1beta- induced AP-1 activation in articular chondrocytes: implications for the regulation of iNOS expression" 19 : 203-214, 2003

22 Tanaka, S., "Factors related to degradation of articular cartilage in osteoarthritis: a review" 27 : 392-399, 1998

23 Tiku, M. L., "Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis" 275 : 20069-20076, 2000

24 Ljubuncic, P., "Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages" 39 : 475-478, 1996

25 Poupon, R. E., "Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis" 113 : 884-890, 1997

26 Huebner, J. L., "Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis" 41 : 877-890, 1998

27 Felson, D. T., "Clinical practice. Osteoarthritis of the knee" 354 : 841-848, 2006

28 Remans, P. H., "CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells" 54 : 3135-3143, 2006

29 Lapenna, D., "Antioxidant properties of ursodeoxycholic acid" 64 : 1661-1667, 2002

30 Lukivskaya, O., "Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis" 51 : 54-59, 2006

31 Song, R. H., "Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5" 56 : 575-585, 2007

32 Kim, J., "A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders" 690 : 12-23, 2010

33 Poupon, R. E., "A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group" 324 : 1548-1554, 1991